Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...
The company has secured contracts worth $1.7M for a recently acquired AI-powered advertising business in its portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback